Objective To determine safety and pharmacodynamics/efficacy of teduglutide in children with intestinal failure associated with short bowel syndrome (SBS-IF). Pediatr 2017;181:102-11).
Treatment-emergent serious adverse event P ediatric short bowel syndrome (SBS) is a malabsorptive condition usually caused by surgical intestinal resection due to congenital abnormalities, vascular insufficiency, or severe inflammatory intestinal disease. 1 The incidence in childhood varies between 0.02% and 1.2% of live births. [1] [2] [3] Although parenteral nutrition (PN) can be a lifesaving therapy, long-term dependence on PN is associated with severe, possibly life-threatening complications, including catheter-related bloodstream infections, loss of central venous access, liver disease, and metabolic bone disease, [4] [5] [6] resulting in impaired quality of life. 7 With advances in the management of intestinal failure (IF) in pediatric patients and the institution of interdisciplinary teams, up to 85% of infants with IF achieve PN independence within 1-3 years with aggressive attempts at enteral feeding [8] [9] [10] [11] ; however, older pediatric patients with intestinal failure associated with short bowel syndrome (SBS-IF) who do not experience sufficient intestinal adaptation to achieve enteral autonomy under the current standard of care (SOC) are less likely to experience further intestinal adaptation sufficient to permit advancements in oral/ enteral feeds or reductions in PN. 11, 12 Additional strategies and therapies that promote intestinal adaptation in these patients are needed for both the subset of infants that fails to adapt within the first year and the older pediatric patients who remain dependent on PN.
Glucagon-like peptide (GLP)-2 is an intestinotrophic hormone that acts by increasing crypt epithelial proliferation, reducing epithelial apoptosis, enhancing visceral blood flow, amplifying nutrient absorption, and slowing intestinal motility. 13 Teduglutide, a GLP-2 analogue with resistance to in vivo degradation, expands the absorptive intestinal epithelium by significantly increasing villus height in adult patients with SBS. [14] [15] [16] This article reports the results of a 12-week, openlabel, dose-finding study that assessed the short-term safety and pharmacodynamics (PD)/efficacy of teduglutide compared with SOC in pediatric patients (aged 1-17 years) with SBS who were dependent on PN for >1 year.
Methods
We performed a 12-week, open-label, multicenter, phase 3 study at 17 sites in the US and the United Kingdom (ClinicalTrials.gov: NCT01952080; EudraCT: 2013-004588-30). The centers featured intestinal rehabilitation programs with multidisciplinary clinical teams experienced in the care of pediatric patients with SBS-IF.
After approval from local institutional review boards and medical ethics committees, centers screened patients aged 1-17 years who had a ≥12-month history of SBS and dependence on PN (defined as PN and/or intravenous fluids) for at least 30% of caloric and/or fluid/electrolyte needs. PN needs were required to be stable at baseline, without any clinically meaningful or substantial reduction in PN or advancement in enteral nutrition (EN; oral and/or tube feeding) for ≥3 months. Key exclusion criteria included body weight below the fifth percentile for age or <10 kg; gastrointestinal (GI) obstruction within 6 months of screening; any major GI surgical intervention within 3 months of screening; history of cancer or clinically significant lymphoproliferative disease (excluding in situ nonaggressive and surgically resected cancer); active Crohn's disease treated with biologic therapy within 6 months of screening or active inflammatory bowel disease treated with immunosuppressant therapy; evidence of pseudo-obstruction or dysmotility syndrome; use of native GLP-2, GLP-1, or human growth hormone within 3 months before screening, or any previous use of teduglutide; and >3 SBS-or PN-related hospital admissions within 3 months or any unscheduled hospital admission within 1 month before screening.
Patients were enrolled in 3 temporally staggered escalating dose cohorts that received respective subcutaneous teduglutide doses of 0.0125 mg/kg/d, 0.025 mg/kg/d, and 0.05 mg/kg/d (Figure 1) . The selection of doses was based on population pharmacokinetic modeling and simulation data that suggested that pediatric patients >1 year of age are likely to require the same dosage used in adults (ie, 0.05 mg/kg/d).
17 Patient compliance with teduglutide dosing was verified during the study by questioning patients or guardians regarding drug administration and by accounting for empty medication vials collected during scheduled study visits. In addition to the 3 dosing cohorts, a fourth observational cohort received SOC. A data safety monitoring board evaluated the safety and tolerability for each sequential dosing cohort at week 4. The data safety monitoring board review established that there were no unexpected safety signals in ≥6 patients before the next cohort proceeded. All patients were screened for ≥2 weeks before the start of treatment to establish baseline characteristics and safety, eligibility, and nutritional support variables.
After screening, study visits occurred weekly for the first 4 weeks and then every 2 weeks through the end of treatment (weeks 5-12; Figure 1 ). To further monitor safety, patients were contacted by telephone at the end of weeks 5, 7, 9, and 11. A final study visit occurred at week 16 (4 weeks after treatment finished). During the study period, patients or their guardians maintained daily diaries to record EN intake. Decisions regarding changes to nutritional and fluid intake were left to the discretion of the primary treating physician, but the study protocol provided guidelines for PN modifications (Table I ; available at www.jpeds.com).
Data Endpoints and Statistical Analyses
Data collected at every study visit included serum electrolytes, liver and pancreatic enzymes, albumin, blood urea nitrogen, creatinine, and weight and height measurements. Treatment-emergent adverse events (TEAEs) and treatmentemergent serious adverse events (TESAEs) were recorded. Samples for teduglutide-specific antibody analysis were drawn at baseline, final treatment visit (≥14 hours after the last dose), and 4 weeks after treatment was completed. Teduglutidespecific antibodies could be non-neutralizing antibodies (ie, those that bind to teduglutide without affecting biological activity) or neutralizing antibodies (ie, those that reduce drug activity). The following PD/efficacy endpoints were used: change in PN requirements, including the number of patients that achieved complete PN independence; change in EN tolerance; Volume 181 • February 2017 and changes in plasma citrulline. PN volume, PN calorie, and EN calorie endpoints were calculated based on provider prescriptions. Changes in hours per day of PN infusion and enteral feeding volumes were based on patient diary data, which were considered more accurate measures of actual patient infusion time and EN consumption than prescribed data. Families were directed to follow prescriptions as closely as possible. Rare changes in patient diaries were made because of technical impediments (eg, pump failure) or caregiver need. EN calorie and volume data were based on formula-based liquid nutrition received orally or via tube feeding only. Other solid foods and liquids were considered ad lib nutrition and were not included in the calculation of EN calories and volume.
Because of the small pool of eligible patients, the study analysis was descriptive in nature and was not designed or sufficiently powered to determine the statistical significance of safety or PD/efficacy endpoints. The intent-to-treat (ITT) population consisted of all patients who enrolled in the trial. The safety population consisted of all patients in the ITT population who received at least 1 dose of teduglutide or SOC. The ITT population was analyzed for PD/efficacy endpoints except for analysis of percentage change from baseline in EN volume and calories (ie, analysis did not include patients who did not receive EN at baseline [n = 10] or did not have EN volume/calorie data recorded at baseline [n = 1], because it is mathematically impossible to calculate a percentage change when the baseline is zero). Patients with no baseline EN intake were included in calculations of actual change in EN volume and calories. Patient electronic case report forms or diaries were used as sources for data collection and management. All data were entered into a preformatted database, verified, quality-checked, and submitted for statistical evaluation.
Adverse events (AEs) were coded with the Medical Dictionary for Regulatory Activities. 18 TEAEs were summarized by system organ class, preferred term, and treatment group by the use of descriptive statistics. TESAEs were tabulated by overall and treatment-related events. Missing safety variables were not imputed. The absolute values and change from baseline in PD/ efficacy variables at each scheduled visit for each treatment group were presented as median (min, max) and also summarized by descriptive summary statistics.
Results
During the study period (November 2013-January 2015), 54 patients were screened and 42 patients were enrolled (Figure 1) (Figure 2 ; available at www.jpeds.com). Of the 42 enrolled patients, 32 were receiving formula-based liquid EN at baseline (n = 4 in the SOC cohort and n = 28 in the combined teduglutide cohorts). Baseline patient demographics are reported in Table II .
Indicators of clinical status remained stable throughout the study period (Table III ; available at www.jpeds.com). All patients experienced at least 1 TEAE. Most patients reported a mild TEAE (95% and 100% of teduglutide-and SOC-treated patients, respectively) or moderate TEAE (57% and 60%). Severe TEAEs were reported by 30% of patients who received teduglutide and by 20% of patients who received SOC. The most common TEAE (Table IV) among all patients receiving teduglutide was vomiting, which was reported more frequently in the 0.05 and 0.025 mg/kg/d cohorts (47% and 36%, respectively, compared with 0% in the 0.0125 mg/kg/d and SOC cohorts). Other commonly reported TEAEs were (25) 1 (7) 1 (7) 4 (11) 5 (12)
Necrotizing enterocolitis 2 (40) 1 (13) 2 (14) 3 (20) 6 (16) 17 were not evident during this smaller pediatric study. There were no discontinuations due to TEAEs. Seventeen patients (46%) in the combined teduglutide cohorts experienced 34 TESAEs, and 3 patients (60%) in the SOC cohort experienced 6 TESAEs ( Table V; (Table VI ; available at www.jpeds.com). At week 16 (4 weeks after teduglutide discontinuation), 2 of these 4 patients had resumed PN and 2 remained PN independent.
On the basis of patient diary data from the ITT population, including those patients who did not receive EN, the EN volume changed by a median of +0. Changes in EN volume and calories from baseline are reported in Figure 3 , C and D. Overall, trends suggestive of PN reductions and EN improvements over baseline values persisted during the first 4 weeks of treatment (Figure 3) . Point estimates of median change in PN weekly volume requirements were increased at week 16 (ie, 4 weeks after teduglutide discontinuation) compared with week 12 (ie, at end of treatment) but remained lower than baseline values in the 2 highest teduglutide dose cohorts: Median plasma citrulline levels at baseline, week 12, and week 16 (4 weeks after teduglutide discontinuation) are reported in Table VII (available at www.jpeds.com). Broad variability in baseline citrulline values was observed, but median change from baseline in citrulline levels increased in all teduglutide cohorts at week 12.
Discussion
Population pharmacokinetic modeling and simulation data indicated that pediatric patients >1 year of age would likely require the same teduglutide dosage approved for adult patients (ie, 0.05 mg/kg/d).
17 Preliminary modeling also suggested that lower doses may show some benefit in children. Therefore, a conservative approach was taken, and 2 lower doses were investigated first.
Teduglutide had a generally good safety profile and was well tolerated by pediatric patients at the doses tested. GI events were reported at a relatively low frequency overall, but most were more common in the 0.025 mg/kg/d and 0.05 mg/kg/d teduglutide dose cohorts than in the SOC cohort (Table IV) . Despite GI events, most patients treated with teduglutide completed the study. The overall safety profile was consistent with the adult SBS population. The most commonly reported TEAEs in the teduglutide-treated population were GI-related AEs, upper respiratory tract infection, catheter-related complications, and pyrexia, all of which were observed in the shortterm studies of teduglutide in adult patients.
19,20 The study protocol included frequent study visits because of the potential for treatment-associated AEs identified in the adult clinical trial program and reported as AEs of special interest in the teduglutide US prescribing information. 17 None of these AEs were observed.
Teduglutide treatment was associated with trends toward decreases in PN requirements and increases in EN intake in a study population that had not experienced any clinically meaningful reductions in PN and minimal or no advance in EN feedings for ≥3 months. Trends suggestive of improvements in EN feedings also were observed in the SOC cohort during this study, in terms of a median 11% increase in EN volume and a 41% increase in EN kcal/kg/d at week 12 vs baseline. Patients receiving SOC in this study likely benefited from intensive, high-frequency patient management at experienced intestinal rehabilitation centers, which are associated with improved outcomes in patients with pediatric SBS. 21 The SOC cohort also was a younger population (2 vs 4 years of age in the pooled teduglutide cohorts) and, therefore, perhaps more capable of endogenous intestinal adaptation.
Citrulline levels also were assessed during this study, but the results were clouded by wide variability of baseline values. In the 0.05 mg/kg/d teduglutide cohort, point estimates showed a median increase in the change of plasma citrulline between baseline and week 12, but the absolute median values for plasma citrulline levels virtually were unchanged. In adults with SBS-IF, treatment with teduglutide has been associated with significant (P < .0001 vs placebo) increases in plasma citrulline.
22
Additional studies with larger sample sizes will need to be conducted to determine whether the same correlation is noted in pediatric patients or to determine whether children need longer courses or greater doses of teduglutide than adults to achieve a consistent effect on plasma citrulline.
Although not directly comparable, the PN decreases (−41% and −25% in the 0.025 and 0.05 mg/kg/d cohorts, respectively) were in range with reductions observed in adults receiving teduglutide 0.05 mg/kg/d in the pivotal phase 3 clinical trial (−32%). 20 In the current study, 4 patients were weaned successfully from PN with teduglutide after up to 12 years of PN dependence. PN had to be resumed in 2 of these patients at week 16 (4 weeks after teduglutide discontinuation), suggestive of a treatment-related improvement while on treatment. Considering the safety profile observed in this study at all doses and trends suggesting decreased PN requirements and EN advancements at the 2 greater teduglutide doses, the benefit/ risk profile for teduglutide was more favorable with 0.025 and 0.05 mg/kg/d teduglutide. Patients in the 0.025 and 0.05 mg/ kg/d cohorts reduced PN volume (L/wk) by 25% to 41% and PN calories (kcal/kg/d) by 45% to 52% while increasing EN volume by 32% to 40% and EN calories by 26% to 63%. In addition, 4 of 29 patients in these 2 cohorts achieved PN independence during the treatment period. Nonetheless, these results are tempered by the recognized limitations of this shortterm, open-label study. The treatment period of this study was only 12 weeks; in adult patients with SBS-IF, teduglutide administered over 30 months yielded continued PN reductions throughout extended treatment. 23 The relatively short study 
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Furthermore, analyses of EN calorie and volume data were based on liquid nutrition only and did not encompass other ad lib enteral consumption. If teduglutide, as anticipated, enhanced ad lib intake and subsequent nutritional absorption, then the assessments of EN volume and calories may have underestimated the potential beneficial impact of teduglutide. In addition, the analyses of actual change in EN calorie and volume data during the study were calculated for the ITT population and thus included those patients who did not receive EN. Reported changes in PN infusion time at week 12 could represent either adjustments in PN volume or modifications of the infusion schedule (ie, cycling), but the accompanying PN volume time course data support trends for reduced PN volume with greater doses of teduglutide. The pool of eligible patients for this study was small, and, as such, the sample size was based on the available patient population rather than on a statistical power calculation. More patients were assigned to the 2 greater-dose cohorts, which were hypothesized to be more likely to elicit clinically relevant effects, than to the 0.0125 mg/ kg/d and SOC cohorts. Moreover, recruitment into the SOC cohort in this open-label study was hindered by lack of interest or perceived benefit among patients and guardians, and this cohort included no patients older than 3 years of age. Thus, the study was not powered sufficiently to determine the statistical significance of safety or PD/efficacy endpoints, and only descriptive statistics were used. Finally, 3 study centers enrolled ≥5 patients (n = 5, 6, and 7, respectively), leading to the possibility of a "center effect," in which the specific practice patterns of those centers may have exerted a disproportionate influence on study results. Many of the aforementioned limitations can be attributed to the fact that pediatric SBS is an orphan condition, making impossible the stratification of the small number of patients enrolled by age, diagnosis, bowel length, or baseline intestinal function.
Effects of teduglutide treatment persisted for at least 4 weeks following drug discontinuation. Although point estimates for PN volume increased at 4 weeks after teduglutide discontinuation compared with end of treatment, median PN volumes remained lower than baseline levels in the 2 greater-dose cohorts (0.025 and 0.05 mg/kg/d). Similarly, compared with end of treatment, trends suggesting advancements in EN feeds were maintained during the 4 weeks after teduglutide discontinuation. Of the 4 patients who achieved enteral autonomy with teduglutide treatment, 2 maintained PN independence at the 4-week follow-up. Study data were not collected past week 16 .
In this initial, 3-month, open-label study, teduglutide treatment was associated with trends toward reductions in PN needs and advancements in EN in children with SBS-IF, particularly at the greater doses tested, 0.025 and 0.05 mg/kg/d. Teduglutide had a favorable safety profile and was well tolerated across all dosing cohorts. A 24-week study that compared the safety and efficacy of 0.025 and 0.05 mg/kg/d teduglutide vs SOC treatment in pediatric patients with SBS-IF (ClinicalTrials.gov, NCT02682381) will yield additional data regarding optimal teduglutide dosing. ■ B efore the release of the rubella vaccine in 1969, more than 20 000 infants in the US were born with congenital rubella syndrome. 1 Affected infants had neurosensory deficits including microcephaly, intellectual disabilities, cataracts, glaucoma, and hearing loss. As with the Zika virus today, there was controversy and a bit of mystery regarding how the virus affected the central nervous system in utero. In 1967, before the availability of advanced neuroimaging, pathologists were the specialists who evaluated brain development and injury.
Fifty years ago in The Journal, pediatric neuropathologists Rorke and Spiro reported a case series of 9 infants who died before age 1 year with confirmed or presumed congenital rubella. The brains of the infants exhibited widespread vascular injury with resulting ischemic lesions in watershed areas, including the periventricular white matter, but no structural malformations of the brain or inflammation were evident. Older infants had poor myelination. The pediatric neuropathologists had rarely seen this constellation of findings. They also found vascular injury to the pulmonary, renal, hepatic, and pancreatic vessels, and speculated that vascular degeneration and resulting ischemia was the primary cause of brain injury with fetal rubella infection. This report was one of many that established the sensorineural consequences of congenital infection with rubella and provided the impetus for public health campaigns that have eliminated endemic rubella in the US. 1 Today, the Zika virus presents a new threat to the fetus. As with congenital rubella, when Zika virus infection first emerged as a threat, there was controversy about whether and how it caused brain injury in the fetus. Our current research toolkit is enhanced by the availability of fetal neuroimaging and identification of the viral genome in brain tissue, 2 but now, as in 1967, careful neuropathologic evaluation of suspected cases continues to be important in establishing disease pathogenesis.
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